Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Hong Kong Med J ; 27(3): 223.e1-223.e2, 2021 Jun.
Article in English | MEDLINE | ID: mdl-34168091
2.
Clin Exp Immunol ; 184(1): 1-10, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26437695

ABSTRACT

Microarray platforms, enabling simultaneous measurement of many allergens with a small serum sample, are potentially powerful tools in allergy diagnostics. We report here the first study comparing a fully automated microarray system, the Microtest allergy system, with a manual microarray platform, Immuno-Solid phase Allergen Chip (ISAC), and two well-established singleplex allergy tests, skin prick test (SPT) and ImmunoCAP, all tested on the same patients. One hundred and three adult allergic patients attending the allergy clinic were included into the study. All patients were tested with four allergy test methods (SPT, ImmunoCAP, Microtest and ISAC 112) and a total of 3485 pairwise test results were analysed and compared. The four methods showed comparable results with a positive/negative agreement of 81-88% for any pair of test methods compared, which is in line with data in the literature. The most prevalent allergens (cat, dog, mite, timothy, birch and peanut) and their individual allergen components revealed an agreement between methods with correlation coefficients between 0·73 and 0·95. All four methods revealed deviating individual patient results for a minority of patients. These results indicate that microarray platforms are efficient and useful tools to characterize the specific immunoglobulin (Ig)E profile of allergic patients using a small volume of serum sample. The results produced by the Microtest system were in agreement with diagnostic tests in current use. Further data collection and evaluation are needed for other populations, geographical regions and allergens.


Subject(s)
Allergens/blood , Hypersensitivity/blood , Hypersensitivity/diagnosis , Immunoglobulin E/blood , Protein Array Analysis/methods , Adult , Animals , Arachis/chemistry , Arachis/immunology , Betula/chemistry , Betula/immunology , Cats , Diagnostic Tests, Routine/instrumentation , Diagnostic Tests, Routine/standards , Dogs , Female , Humans , Hypersensitivity/immunology , Male , Middle Aged , Mites/chemistry , Mites/immunology , Phleum/chemistry , Phleum/immunology , Protein Array Analysis/instrumentation , Protein Array Analysis/standards , Sensitivity and Specificity
3.
Hong Kong Med J ; 16(6): 455-62, 2010 Dec.
Article in English | MEDLINE | ID: mdl-21135422

ABSTRACT

OBJECTIVES: To assess time management of stroke thrombolysis triage and functional outcomes in patients receiving recombinant tissue plasminogen activator for hyperacute stroke, and identify bottlenecks in delivery of the treatment. DESIGN: Prospective study. SETTING: A university teaching hospital in Hong Kong. PATIENTS: Patients with suspected hyperacute stroke referred to the stroke thrombolysis team during October 2008 to September 2009. MAIN OUTCOME MEASURES: Time performance records including door-to-stroke team, door-to-needle, and onset-to-thrombolysis times. Functional outcomes by modified Rankin Scale score at 3 months, and thrombolysis-related complications including haemorrhagic transformations and mortality. RESULTS: During the 12-month period, 95 thrombolysis calls were received; recombinant tissue plasminogen activator was given intravenously to 17 (18%) of the patients and intra-arterially to 11 (12%). The mean (standard deviation) door-to-stroke team and the door-to-needle times for intravenous recombinant tissue plasminogen activator patients were 33 (25) and 80 (25) minutes, respectively; both were about 20 minutes longer than that recommended by the National Institute of Neurological Disorders and Stroke. The mean National Institute of Health Stroke Scale score for patients received intravenous recombinant tissue plasminogen activator was 16 (standard deviation, 7). The mean (standard deviation) onset-to-treatment time was 144 (42) minutes. Nine (53%) patients who received intravenous recombinant tissue plasminogen activator achieved favourable outcomes at 3 months, with a modified Rankin Scale score of 0 to 1. Symptomatic haemorrhage and mortality occurred in one (6%) patient. CONCLUSION: A dedicated stroke triage pathway is essential to ensure efficient and safe delivery of thrombolysis therapy. Improvements in door-to-stroke team time through integration with emergency medicine staff and neuroradiologists may improve thrombolysis eligibility.


Subject(s)
Stroke/drug therapy , Thrombolytic Therapy , Triage , Aged , Female , Humans , Male , Middle Aged , Prospective Studies , Stroke/mortality , Thrombolytic Therapy/adverse effects , Time Management , Tissue Plasminogen Activator/therapeutic use
4.
Opt Lett ; 22(14): 1113-5, 1997 Jul 15.
Article in English | MEDLINE | ID: mdl-18185768

ABSTRACT

The multiple, active, computer-generated hologram (MACH) is a novel device combining the attributes of electrically controllable diffraction gratings and computer-generated holograms. The version discussed here consists of a surface relief transmitting structure immersed in a nematic liquid crystal and sandwiched between two, planar indium tin oxide electrodes. Under control of a single applied voltage, the device can selectively generate any one of a number of desired, uncorrelated optical wave fronts. The device principles are discussed and experimental results presented. There is a brief discussion of the relative merits of the MACH and electrically addressed spatial light modulators.

SELECTION OF CITATIONS
SEARCH DETAIL
...